RecruitingNot ApplicableNCT06717542

Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.

Tissue Analysis (Histological, Ultrastructural and Molecular) of Liver Grafts as a Predictor of Transplant Outcome.


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

200 participants

Start Date

Jan 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Despite the good clinical results in terms of outcome with the application of HOPE prior to liver transplantation, very little is still known about the phenotypic and molecular changes that occur during perfusion/preservation during HOPE, particularly with regard to endothelial trophism and activation. Delving into these aspects would be very useful to allow personalised perfusion treatments in the future, thus improving the outcome of transplantation.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • For Donors:
  • Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis.
  • HOPE performed on the liver graft prior to transplantation.
  • For Recipients:
  • Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis.
  • Age greater than/equal to 18 years.

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESThistochemical and immunohistochemical analysis

2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1

DIAGNOSTIC_TESTRT-PCR

Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).


Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06717542


Related Trials